Reviewing InspireMD (NYSE:NSPR) & Motus GI (NASDAQ:MOTS)

Motus GI (NASDAQ:MOTS) and InspireMD (NYSE:NSPR) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, risk, profitability, valuation, dividends and earnings.

Earnings and Valuation

This table compares Motus GI and InspireMD”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Motus GI	$319,000.00	0.00	-$12.87 million	($14.69)	N/A
InspireMD	$7.78 million	8.61	-$19.92 million	($0.84)	-1.88

Motus GI has higher earnings, but lower revenue than InspireMD. InspireMD is trading at a lower price-to-earnings ratio than Motus GI, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

20.1% of Motus GI shares are owned by institutional investors. Comparatively, 44.8% of InspireMD shares are owned by institutional investors. 0.3% of Motus GI shares are owned by company insiders. Comparatively, 34.1% of InspireMD shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Motus GI and InspireMD’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Motus GI	N/A	N/A	N/A
InspireMD	-413.96%	-69.42%	-57.68%

Volatility and Risk

Motus GI has a beta of 0.82, indicating that its stock price is 18% less volatile than the S&P 500. Comparatively, InspireMD has a beta of 0.72, indicating that its stock price is 28% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Motus GI and InspireMD, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Motus GI	0	0	0	0	0.00
InspireMD	0	0	1	0	3.00

InspireMD has a consensus target price of $4.00, suggesting a potential upside of 153.16%. Given InspireMD’s stronger consensus rating and higher possible upside, analysts plainly believe InspireMD is more favorable than Motus GI.

Summary

InspireMD beats Motus GI on 7 of the 13 factors compared between the two stocks.

About Motus GI

Motus GI Holdings, Inc. operates as a medical technology company in the United States. It develops Pure-Vu system, a medical device to facilitate the cleansing of a poorly prepared gastrointestinal tract during the colonoscopy and facilitates upper gastrointestinal endoscopy procedures. The company was formerly known as Eight-Ten Merger Corp. and changed its name to Motus GI Holdings, Inc. in November 2016. The company was founded in 2008 and is based in Fort Lauderdale, Florida.

About InspireMD

InspireMD, Inc., a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions. InspireMD, Inc. has a strategic agreement with Jacobs Institute to execute an early feasibility study of CGuard Prime for the treatment of acute stroke patients with tandem lesions. The company sells its products through local distribution partners. InspireMD, Inc. was founded in 2005 and is headquartered in Tel Aviv-Yafo, Israel.